Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Depressive Disorder, Treatment-Resistant: early-phase trial registry
3 of 10 indexed Depressive Disorder, Treatment-Resistant trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #1,724 of 28,707 conditions by registered trial count.
10 US clinical trials · 3 currently recruiting · #1,724 of 28,707 conditions by registered trial count
Depressive Disorder, Treatment-Resistant: 10 US clinical trials tracked, 3 recruiting.
Depressive Disorder, Treatment-Resistant is the subject of 10 registered US clinical trials on ClinicalTrials.gov, 3 of them currently open to new participants. 2 are in Phase 3-4 (later-stage) and 5 in Phase 1-2 (earlier-stage). The most active sponsor is Janssen Research & Development, running 2 of these trials.
Enrollment posture brief
Registry condition depressive-disorder-treatment-resistant
OPEN 3 | RECR 30% | LATE 2 | EARLY 5 | RANK #1724 | SPON 2
Volume-matched condition peers
Nearest open-share peer: Adrenocortical Carcinoma (30% recruiting · 10 trials)
Depressive Disorder, Treatment-Resistant lists 3 open slots (30% of 10 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Depressive Disorder, Treatment-Resistant on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Depressive Disorder, Treatment-Resistant is recruiting below its size-band peers.
3 of 10 indexed trials (30%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Depressive Disorder, Treatment-Resistant research.
Janssen Research & Development accounts for 2 of 10 trials (20%). 9 distinct sponsors appear on at least one study for this condition label.
-
Typical Depressive Disorder, Treatment-Resistant enrolment sits around 122 participants.
Median target enrolment is 122 among the 10 trials that report a genuine target (sentinel values excluded). 4 of those (40%) plan for fewer than 100 participants.
-
Depressive Disorder, Treatment-Resistant research is mostly interventional.
9 interventional and 1 observational studies make up this index (90% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
10 total, page 1 of 1
ACP-211 Monotherapy for Major Depressive Disorder With Inadequate Antidepressant Response
ACADIA Pharmaceuticals
NCT07284667
Investigation of the Antidepressant Effects of (2R,6R)-HNK, an Enhancer of Synaptic Glutamate Release, in Treatment-Resistant Depression
National Institute of Mental Health (NIMH)
NCT06511908
Intravenous Ketamine for Treatment-Resistant Depression
Mayo Clinic
NCT06668571
Dopaminergic Dysfunction in Late-Life Depression
Vanderbilt University Medical Center
NCT04469959
Improving Brain Stimulation Through Imaging
VA Office of Research and Development
NCT03851380
Adaptive tDCS for Treatment-Resistant MDD
Washington University School of Medicine
NCT02942368
A Long-term Safety Study of Esketamine Nasal Spray in Treatment-resistant Depression
Janssen Research & Development
NCT02782104
A Study to Evaluate the Efficacy, Pharmacokinetics, Safety and Tolerability of Flexible Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant Depression
Janssen Research & Development
NCT03434041
Efficacy, Safety, and Tolerability Study of AVP-786 as an Adjunctive Therapy in Patients With Major Depressive Disorder With an Inadequate Response to Antidepressant Treatment
Avanir Pharmaceuticals
NCT02153502
Low Field Magnetic Stimulation (LFMS) in Subjects With Treatment-Resistant Depression (TRD)
Tal Medical
NCT02452892
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 2 | 5 |
| Phase 3 | 2 |
Top Sponsors
Named interventions
Most-linked intervention names on Depressive Disorder, Treatment-Resistant records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Depressive Disorder, Treatment-Resistant trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Depressive Disorder, Treatment-Resistant page
10 registered trials, 3 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 3 Depressive Disorder, Treatment-Resistant trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Janssen Research & Development sponsors the most Depressive Disorder, Treatment-Resistant trials on record, review their full trial history before evaluating a specific study. See Janssen Research & Development's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Depressive Disorder, Treatment-Resistant condition card totals 10 registered trials; most-linked intervention Placebo; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.